General Assembly
Report

19. June 2017
# Table of Content

1. Presidential report
2. Secretary-General’s report
3. Vice-presidents’ reports
4. Treasurer’s report
5. Election of Executive Committee 2017-2019
6. Presidential Programme 2017-2019
7. Any other business
Presidential report
Innovative approach
Strategy 2015-2017

Building a **platform** to enhance EAACI’s profile as an attractive partner for EU bodies, relevant companies and future members

- **FOCUS ON NETWORKING**

1. **Scientific output** – Guidelines
2. **Scientific Dissemination**: EAACI journals and books
3. Membership
4. Governance project
5. **Scientific vision**: precision medicine & precision health
6. EU outreach

**Ensuring financial stability and viability**
1 - Best Practice Guidelines

Food Allergy and Anaphylaxis Guidelines for Clinical Practice

ALLERGEN IMMUNOTHERAPY GUIDELINES FOR CLINICAL PRACTICE
June, 2017 - October 2017

- Will support health care professionals’ use of AIT
- Will highlight benefits at public and policy maker levels
- Will promote health economics of AIT
1 – NEW Guidelines Committee

AIM: oversee the successful generation of new guidelines

- Will support getting appraisal of evidence – SR
- Will provide internal training
- Will facilitate collaborative projects as new guidelines
- Will design and support implementation
2-EAACI Scientific dissemination

Clinical and Translational Allergy
NEW Impact factor 3.23
EAACI Membership : 10,000
Young Organization

- Under 36: 46%
- Between 36-60: 45%
- Over 60: 9%
EAACI Membership Profile

- Male: 58%
- Female: 42%

46%
3 - Initiatives for Membership

Nurturing Future Leaders

Leadership Course

Talent Development Course for Juniors

4th Women in Science Symposium

Copenhagen 2014--Helsinki 2017

Nurturing Senior leaders: Master Class model, Hands-on Courses

Vienna 2016, Helsinki, 2017
INTEGRATED APPROACH (i)

Joining forces in building strong alliances

- National Allergy Societies Committee: 54
- International Societies Council: 16
- Patient’s organization committee: 28
INTEGRATED APPROACH (ii)

Joining forces in building strong alliances

Increased projects with Sister Societies:
AAAIAI, ERS, APAPARI, APAACI, WAO

Outreach to Primary care: UEMO

Collaboration for advocacy with Industry partners
Governance project

- NEW Structure in place: pilot phase of 2 years
- NEW Governance Committee: supervising on-going process
- Revision of the Constitution: to be circulated to the membership
- Revision of the Bylaws: on-going
- Promoting efficiency and governance at the Headquarters
5- Scientific Vision

Precision Medicine in Allergy

Practall: 1- Asthma, Rhinitis and Atopic Dermatitis
2- Food allergy, anaphylaxis, drug allergy

• Personalized care
• Prediction of success
• Prevention (prim/sec/tert)
• Participation of patient

 Networks of Centres

• Facilitating implementation of best standards of practice
• Allergy Comprehensive Centres

APPLICABLE TO ALLERGIES & AIRWAYS DISEASES
6. EU Outreach
Advocacy Platform

Policy events of the MEP Interest Group in EU Parliament

Launch CALL TO ACTION
April 26th

High Level EU Business lunch at the Annual Congress June 19

EU Liaison Office

Strong alliances: National Societies & Patient Organisations

Do you have allergies? 150 million EU citizens have allergy, the most common chronic disease in Europe

TEST YOUR ALLERGIES 2016 – Test, Inform, Prevent

Exhibition and Allergy Testing: 26–28 April 2016, Mezzanine Yehudi Menuhin (PHS, Floor 2 below plenary hall)
Opening Cocktail Meeting: 26 April 2016, 17:00–19:00, Members Salon
A POLITICAL CALL TO ACTION IN EUROPE

Key stakeholders joining hands to initiate the Call and promote its endorsement campaign

Policymakers
European Parliament
Interest Group on Allergy and Asthma

Healthcare Professionals

Patients

- To European Member States
- To European Commission
- To European Parliament
- To patients, healthcare stakeholders, and civil society
www.CallAllergyAsthma.eu – by September 30th

CLICK TO SIGN AS

POLICY MAKERS
Individuals working in an EU institution (e.g. European Commission, Parliament, Council), or in a national government or administration (e.g. Ministry of health, public health institute, others).

ORGANISATION
Non-profit organisation active in a relevant field (e.g. patients organisations, civil society and consumer organisations, medical associations, health and environment NGOs, healthcare trade associations).

INDIVIDUAL
Citizen supporter of the cause and signing in his/her own name.
Ensuring financial sustainability

- Prioritization of projects according to the strategic priorities
- Regular Strategic meetings with industry partners
- 2 NEW Founder Sponsors: PLATINUM
- 1 NEW Founder sponsor: GOLD
- Ensuring development of flagships focused meetings and overall no budget deficit for meetings
- Ensuring transparency in accounting
Thank you for your trust
Approval of the Presidential Report
Secretary-General’s report
New Governance Model

- Organisational structure
- Roles and responsibilities

Revision of the Constitution and Bylaws
EAACI Organisational Structure

Sections (6)
- Basic & Clinical Immunology
- Asthma
- Pediatric
- Dermatology
- ENT
- Junior Members Assembly

WG on Immunodeficiencies
WG on Infections
WG on Biologicals
WG on Allergy, Asthma & Sports
WG on Ocular Allergy

Interest Groups (6)
- Food Allergy
- Drug Allergy
- Allergen Immunotherapy
- Environmental & Occupational Allergy
- Allergy Diagnosis & Systems Medicine
- IG Allied Health & Primary Care

- WG on Eosinophilic Esophagitis
- WG on Insect Venom Hypersensitivity
- WG on Epidemiology
- WG on Aerobiology and Pollution
- WG on Genomics and Proteomics
- WG on Comparative Veterinary Allergology
- WG on Allied Health
- WG on Primary Care
EAACI HQ - Organigram

Executive Director
Sue C. C. Paredi

Executive Assistant
Jeanette Kobler

Executive Trainee
Isabel Heitmeyer

Marketing & Communications Manager
Charlotte Horder

MarCom Officer
Kendra Zuber

Publications, Public Relations & Public Affairs Manager
Lena Geltenbort-Rost

Congress & Events Manager
Veronika Topolska

Congress & Events Specialist
vacant

Congress & Events Officer
Enna Heller

Conrad & Events Officer
Francesca Spinedi

Education & Specialty Manager
a.i. Sue C. C. Paredi

Education Officer
Katerina Klimogianni

Education Officer
vacant

IT Project Manager & Marketing Technologist
Charalampos Kostaras (Haris)

Finance & HR
Rebo Treuhand
Elisabeth Schmotzer

Payroll / Debtors
vacant

Creditor
Theres Brühnschweiler

valid 1.6.2017
EAACI HQ - Organisation Headquarters

Sue C. C. Paredi
Haris Kostaras
Lena Geltenbort-Rost
Veronika Topolska
Jeanette Kobler
Katerina Klimogianni
Charlotte Horder
Enna Heller
Isabel Heitmeyer
Kendra Zuber
Francesca Spinedi
Approval of the Secretary General’s Report
Vice-presidents’ reports
Vice-president Congresses
## Facts and Figures

<table>
<thead>
<tr>
<th>Year</th>
<th>Congress</th>
<th>Total Attendees</th>
<th>Abstracts</th>
<th>Late Breaking Abstracts</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>Istanbul</td>
<td>7,874</td>
<td>1,886</td>
<td>264</td>
<td>2,150</td>
</tr>
<tr>
<td>2012</td>
<td>Geneva</td>
<td>6,217</td>
<td>1,717</td>
<td>270</td>
<td>1,987</td>
</tr>
<tr>
<td>2013</td>
<td>Milan</td>
<td>7,696</td>
<td>1,678</td>
<td>290</td>
<td>1,968</td>
</tr>
<tr>
<td>2014</td>
<td>Copenhagen</td>
<td>7,403</td>
<td>1,429</td>
<td>438</td>
<td>1,867</td>
</tr>
<tr>
<td>2015</td>
<td>Barcelona</td>
<td>7,667</td>
<td>1,520</td>
<td>330</td>
<td>1,850</td>
</tr>
<tr>
<td>2016</td>
<td>Vienna</td>
<td>7,791</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Helsinki</td>
<td>7,997</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>7,874</td>
<td>6,217</td>
<td>7,696</td>
<td>7,403</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7,791</td>
<td>1,850</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7,997</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In order to improve the quality of Thematic Poster Sessions (TPS), EAACI has decided to invest into the **Interacbio App**, which can be used on delegates’ own mobile device for acoustically clear listening of Thematic Poster Presentations.
CME Credits & Technology used at EAACI (Waytation)

Scan-free automated certification process at the EAACI 2017 congress
Provider of digital solution is company Waytation

3 simple steps on how to automatically collect your CME credits with EAACI CME:

1) Collect your lanyard (with badge) in the registration area
2) Pick up your tag (chip) at the CME Counter and synchronize it with your badge
3) Attend EAACI Scientific Sessions each day and collect your CME credits automatically

Advantages:

✓ No more hand scanning of badges in front of each session room
✓ Additionally, it enables each participant to receive an overview of each session they personally attended
✓ EAACI will gain valuable insights about the congress programme and exhibition; This will allow the Scientific Programme Committee to constantly improve future EAACI congresses and to recognise popular topics amongst all attendees
# EAACI Congress 2018: Munich

26 – 30 May 2018 - ICM Messe München

## Time line

<table>
<thead>
<tr>
<th>Speaker Management</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker invitations (PL, SYM, WS, PG, LL, P&amp;C)</td>
<td>July / August 2017</td>
</tr>
<tr>
<td>Scientific Programme and Registration online</td>
<td>25 October 2017</td>
</tr>
<tr>
<td>Chair Invitations (PL, SYM, WS, PG, LL, P&amp;C)</td>
<td>begin October 2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regular abstract Submission</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Start Abstract Submission</td>
<td>23 October 2017</td>
</tr>
<tr>
<td>Deadline for Abstract Submission</td>
<td>15 January 2018</td>
</tr>
<tr>
<td>Late-breaking abstract submission</td>
<td>15 - 28 February 2018</td>
</tr>
</tbody>
</table>

| Meetings | Marathon Meeting | 16-17 February |

Congress Local Chair: Carsten Schmidt-Weber, SPC- coordinator: Susanne Halken

Contract with the venue has been finalized

ICM Messe München, Hall B1
Past Focused Meetings 2016

**FAAM 2016**

13 – 15 October 2016 – Rome, Italy
- Attendees: 1,117
- Accepted abstracts: 270 \(\text{(presented: oral 17, posters 253)}\)
- Countries: 63

**ISAF 2016**

17 – 19 November 2016 – Manchester, UK
- Attendees: 252
- Accepted abstracts: 50 \(\text{(presented oral: 9, posters 32)}\)
- Countries: 36
Past Focused Meetings 2017

SERIN 2017

30 March – 1 April 2017 – Düsseldorf, Germany
- Attendees: 115
- Accepted abstracts: 39 (presented: oral 13, posters 18)
- Countries: 63

SAM 2017

27 – 29 April 2017 – Zurich, Switzerland
- Attendees: 261
- Accepted abstracts: 45 (presented oral: 15, posters 37)
- Countries: 42
Upcoming Focused Meetings 2017

PAAM 2017

26 – 28 October 2017 – London, UK
Chairs: George du Toit, UK and Montserrat Alvaro Lozano, ES

ISMA 2017

9 – 11 November 2017 – Luxembourg
Chair: Makurs Ollert, Lux
Upcoming Focused Meetings 2018

**DHM 2018**

19 – 21 April 2018 – Amsterdam, the Netherlands  
Chairs: Ingrid Terreehorst, NL, Maria J. Torres, ES  
and Knut Brockow, DE

**FAAM 2018**

18 – 20 October 2018 – Copenhagen, Denmark  
Chairs: Carsten Bindslev-Jensen, DK and Lars K. Poulsen, DK
Vice-president Education & Specialty
<table>
<thead>
<tr>
<th>Allergy Schools / Master Classes - Completed</th>
<th>Date</th>
<th>Registered Participants</th>
<th>Accepted Abstracts</th>
<th>Speakers</th>
<th>CME Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy School on Drug Allergy in Children, Belgrade, Serbia</td>
<td>22-24 September 2016</td>
<td>87</td>
<td>22</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Master Class on Translational Immunology in Allergic Diseases, Zurich, Switzerland</td>
<td>21-22 October 2016</td>
<td>45</td>
<td>N/A</td>
<td>19</td>
<td>9</td>
</tr>
<tr>
<td>Winter School on Basic Immunology Research in Allergy and Clinical Immunology, Sierra Nevada, Spain</td>
<td>26-29 January 2017</td>
<td>72</td>
<td>67</td>
<td>6 + Section board</td>
<td>16</td>
</tr>
<tr>
<td>Allergy School on Eosinophilic Esophagitis, Rotterdam-Vlaardingen, The Netherlands</td>
<td>16-18 March 2017</td>
<td>87 (max)</td>
<td>17</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>Master Class on Primary Immunodeficiencies, Prague, Czech Republic</td>
<td>7 - 8 April 2017</td>
<td>49 (max)</td>
<td>6 case reports</td>
<td>11</td>
<td>8</td>
</tr>
</tbody>
</table>
## Allergy Schools and Master Classes: Upcoming 2017-2018

<table>
<thead>
<tr>
<th>Allergy Schools / Master Classes - Upcoming</th>
<th>Date</th>
<th>Speaker invitations</th>
<th>Event publicised</th>
<th>Registrations</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food Allergy Training Course “Prevention and Treatment of Food Allergy”, Manchester, United Kingdom</td>
<td>14-16 September 2017</td>
<td>20.03.2017</td>
<td>17.03.2017</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Winter School on Basic Immunology Research in Allergy and Clinical Immunology, Saas-Fee, Switzerland</td>
<td>25-28 January 2018</td>
<td>26.04.2017</td>
<td>22.05.2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergy School on Aerobiology and Pollution, Dubrovnik, Croatia</td>
<td>15-17 March 2018</td>
<td>30.07.2017</td>
<td>30.07.3017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Master Class on Occupational Allergy, Madrid, Spain</td>
<td>29-30 September 2017</td>
<td>23.03.2017</td>
<td>31.03.2017</td>
<td>9</td>
<td>N/A</td>
</tr>
<tr>
<td>Master Class on Biologicals, Prague, Czech Republic</td>
<td>13-14 April 2018</td>
<td>02.06.2017</td>
<td>08.06.2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Master Class on Practical Allergy Diagnostics, Ebsdorfergrund, Germany</td>
<td>23-24 March 2018</td>
<td>15.07.2017</td>
<td>15.07.2017</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## EAACI/UEMS Knowledge Examination update

<table>
<thead>
<tr>
<th>EAACI/UEMS Knowledge Examination</th>
<th>Vienna Congress, 2016</th>
<th>Helsinki Congress, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Applications</td>
<td>56</td>
<td>68</td>
</tr>
<tr>
<td>No. of EAACI members</td>
<td>50</td>
<td>65</td>
</tr>
<tr>
<td>No. of Non-Members</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>No. of European Countries</td>
<td>15</td>
<td>14</td>
</tr>
<tr>
<td>No. of Non-European Countries</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>(South Africa, Mexico, Russia, Thailand, Japan, India, Turkey)</td>
<td>(Argentina, South Africa, Iran, India, Turkey, Russia, Saudi Arabia, Paraguay, Sri Lanka, Namibia, Jordan, Egypt, Chile, Canada and Brazil)</td>
</tr>
<tr>
<td>No. of Actual Registrations (paid)</td>
<td>50</td>
<td>61</td>
</tr>
<tr>
<td>Requested and Received UEMS</td>
<td>15</td>
<td>22</td>
</tr>
<tr>
<td>Financial Support</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Carsten Schmidt-Weber
The roadmap for Allergology in Europe

- EAACI Taskforce on subspecialties of Allergology
- EAACI Taskforce on allergy services in Europe
- SWOT analysis
- European Training requirements (ETR) for the specialty of Allergology
No subspecialty or full specialty:
Belgium, Denmark, Ireland, Austria, Slovenia.

Subspecialty of allergology:
Estonia, Finland, Germany, Hungary, Netherlands, Turkey.

Full specialty of allergology:
Bulgaria, Croatia, Cyprus, Czech Republic, France, Great Britain, Greece, Italy, Lithuania, Luxemburg, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland.
Total number of specialists

UEMS S&B and NASC survey  
- Full specialty  
- Subspecialty  
- None
Countries with combined Allergology & Clin Imm
• Faster accreditation process
• Maximum of 8 ECMEC’s per day
• Accreditation of
  • e-Learning Modules (ELM)
  • e-platform (at least 10 ELMs)
  • Educational App
  • Educational e-Library
EAACI Allergen Immunotherapy Guidelines

Allergen Immunotherapy Guidelines
Part 1: Systematic reviews

Translating knowledge into clinical practice

European Academy of Allergy and Clinical Immunology

Chair: Antonella Muraro

- Asthma
- Rhinoconjunctivitis
- Prevention
- Venom
- Food allergy
- Primary care
- Regulatory
## Nomination of CME and Exam Committee Chairs 2017-19

<table>
<thead>
<tr>
<th>Exam Committee Chairperson</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Khaitov, Musa R.</td>
<td>Exam Committee Chair</td>
</tr>
<tr>
<td>Czarnecka-Operacz, Magdalena</td>
<td>CME Committee Chair</td>
</tr>
</tbody>
</table>
New educational tools: perspectives

• Webinars
• Hybrid meetings
• Exam preparation (Online)
• Online courses (f Target audience)
Vice-president
Communication and Membership
EAACI journals – Allergy and PAI

New contract with Wiley 2017-2020
• Co-ownership
• Significant increase in revenue (6X)

Open Call for Editors
EAACI journals – Clinical and Translational Allergy (CTA)

Many congratulations for the IF

Ongoing negotiations with the publisher (BMC)

• Immediate ownership
• Sharing resources (editors fee, secretarial support)
• Revised marketing strategy
Membership Report - Number of active members – 2017 (May)

2001: 2921
2002: 3478
2003: 3873
2004: 4206
2005: 4466
2006: 4786
2007: 5103
2008: 5300
2009: 5373
2010: 5868
2011: 6646
2012: 7401
2013: 7489
2014: 8056
2015: 9101
2016: 9326
2017: 10258

(May)
Membership Report - Members in good standing

- **2014**: 6710
- **2015**: 7241
- **2016**: 7328
- **2017 (May)**: 7165
Gender and age distribution

- 58% Male
- 42% Female

- <25: 2%
- 25-30: 18%
- 31-35: 26%
- 36-45: 25%
- 46-50: 7%
- 51-60: 9%
- 2% Junior Members (46%)

- 13%
64 National Societies

- WG Specialty:
- WG Health Economics
- WG Guidelines
- WG EU Lobbying
Books

Launch of the AIT Guidelines Part 1

188 pages systematic reviews in
• Prevention of allergy
• Venom immunotherapy
• IgE-food allergy
• Asthma
• Rhinoconjunctivitis
Communication Platforms

Network  Link  Message  Letter  Report
Mobile  Contact  Speech  Internet  Email
Social  Connection  Chat  Web
Dialogue  Announcement  News  Technology
LinkedIn: 3,115
Instagram: 542
YouTube channel: 23,043 views
Approval of the Vice-Presidents’ Reports
Treasurer’s report
Own Capital accumulated profit over the years

<table>
<thead>
<tr>
<th>'000 €</th>
<th>as of 31.12.</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2016</td>
<td>3'853.0</td>
</tr>
<tr>
<td>December 2015</td>
<td>3'790.5</td>
</tr>
<tr>
<td>December 2014</td>
<td>3'994.1</td>
</tr>
<tr>
<td>December 2013</td>
<td>2'862.4</td>
</tr>
<tr>
<td>December 2012</td>
<td>3'247.3</td>
</tr>
<tr>
<td>December 2011</td>
<td>3'192.2</td>
</tr>
<tr>
<td>December 2010</td>
<td>2'677.3</td>
</tr>
<tr>
<td>December 2009</td>
<td>2'658.8</td>
</tr>
<tr>
<td>December 2008</td>
<td>2'270.0</td>
</tr>
</tbody>
</table>

Capital as of 31.12.2015: 3'790.5
Profit 2016 prior ZKB: 106.6
Adjustment ZKB invest: -44.1
New capital as of 31.12.2016: 3'853.0
Capital invested at ZKB
development of Market Value

<table>
<thead>
<tr>
<th>Year</th>
<th>Nominal Capital</th>
<th>Market Value at End of Year</th>
<th>Interest received</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>2310</td>
<td>2,477</td>
<td>80.7</td>
</tr>
<tr>
<td>2012</td>
<td>2550</td>
<td>2,797</td>
<td>101.1</td>
</tr>
<tr>
<td>2013</td>
<td>2950</td>
<td>3,251</td>
<td>116.7</td>
</tr>
<tr>
<td>2014</td>
<td>2950</td>
<td>3,325</td>
<td>115.4</td>
</tr>
<tr>
<td>2015</td>
<td>3040</td>
<td>3,193</td>
<td>106.8</td>
</tr>
<tr>
<td>2016</td>
<td>3110</td>
<td>3,314</td>
<td>111.7</td>
</tr>
</tbody>
</table>

Interest received in %: 3.49% 3.96% 3.96% 3.91% 3.51% 3.59%
<table>
<thead>
<tr>
<th>Statement 2016 - Summary</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Statement December</th>
<th>Budget 2016 adj. Approved ExCom June 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Income</strong></td>
<td>4'450'303</td>
<td>4'332'800</td>
</tr>
<tr>
<td><strong>Total Expenditures</strong></td>
<td>4'343'739</td>
<td>4'975'820</td>
</tr>
<tr>
<td>projects on hold</td>
<td>0</td>
<td>82'300</td>
</tr>
<tr>
<td>Adjustment ZKB investment to market value</td>
<td>-44'116</td>
<td>0</td>
</tr>
<tr>
<td><strong>+Surplus/-Deficit</strong></td>
<td>62'448</td>
<td>-725'320</td>
</tr>
<tr>
<td>Income Description</td>
<td>Statement December</td>
<td>Budget 2016 adj. Approved ExCom June 2016</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Total Income</td>
<td>4'450'303</td>
<td>4'332'800</td>
</tr>
<tr>
<td>Membership Subscription</td>
<td>309'900</td>
<td>320'000</td>
</tr>
<tr>
<td>Income from Founder Sponsor Members</td>
<td>1'911'100</td>
<td>1'805'800</td>
</tr>
<tr>
<td>Income from Corporate Sponsor</td>
<td>80'000</td>
<td>80'000</td>
</tr>
<tr>
<td>Fundraising</td>
<td>45'194</td>
<td>50'000</td>
</tr>
<tr>
<td>Congresses</td>
<td>1'300'000</td>
<td>1'400'000</td>
</tr>
<tr>
<td>Focussed Meetings</td>
<td>169'759</td>
<td>90'000</td>
</tr>
<tr>
<td>Education group</td>
<td>20'238</td>
<td>19'000</td>
</tr>
<tr>
<td>Communication group</td>
<td>66'971</td>
<td>145'000</td>
</tr>
<tr>
<td>Other Income</td>
<td>59'500</td>
<td>30'000</td>
</tr>
<tr>
<td>Interest / Currency</td>
<td>111'720</td>
<td>93'000</td>
</tr>
<tr>
<td>Extraordinary Income</td>
<td>375'921</td>
<td>300'000</td>
</tr>
</tbody>
</table>
Statement 2016 - Expenses as of December 31st

<table>
<thead>
<tr>
<th>Description</th>
<th>Statement December</th>
<th>Budget 2016 adj. Approved ExCom June 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Expenditures</td>
<td>4'343'739</td>
<td>4'975'820</td>
</tr>
<tr>
<td>Total Congresses</td>
<td>39'390</td>
<td>40'000</td>
</tr>
<tr>
<td>Total Task forces/New Projects</td>
<td>718'521</td>
<td>1'147'430</td>
</tr>
<tr>
<td>Total support of External Events</td>
<td>34'467</td>
<td>0</td>
</tr>
<tr>
<td>Total Communications &amp; Membership</td>
<td>610'085</td>
<td>768'050</td>
</tr>
<tr>
<td>Total Education Group</td>
<td>381'952</td>
<td>578'100</td>
</tr>
<tr>
<td>Total External Strategic Activities</td>
<td>178'919</td>
<td>135'000</td>
</tr>
<tr>
<td>Total Administration and ExCom</td>
<td>585'904</td>
<td>623'500</td>
</tr>
<tr>
<td>Total Headquarter</td>
<td>1'373'185</td>
<td>1'519'840</td>
</tr>
<tr>
<td>Total Organisation Growth &amp; Other</td>
<td>109'389</td>
<td>113'900</td>
</tr>
<tr>
<td>Total Contingency</td>
<td>311'926</td>
<td>50'000</td>
</tr>
</tbody>
</table>
Audit Report as of 26th April, 2017

European Academy of Allergy and Clinical Immunology, 2014

As monetary auditor, we have audited the financial statements, balance sheet and income statement of the European Academy of Allergy and Clinical Immunology for the year ended 31 December 2016.

These financial statements (balance sheet and income statement) are the responsibility of the Board of Directors.

Our responsibility is to express an opinion on these financial statements based on an audit. Our audit was conducted in accordance with auditing standards issued by the Auditing Practices Board, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. The audit included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. We have assessed the accounting policies and significant estimates made and the overall financial statement presentation. The above lines and provides a reasonable basis for our opinion.

In our opinion, the financial statements and financial statements (balance sheet and income statement) are free from material misstatement.

SHÁ Balázs, Apr 16, 2017

[Signatures]
Approval
of the Treasurer’s Report
Election of Executive Committee 2017-2019
EAACI Board of Officers (BoO) 2017-2019

EAACI President
Ioana Agache
Romania
ibrumaru@unitbv.ro

EAACI Secretary General
Peter Hellings
Belgium
peter.hellings@med.kuleuven.ac.be

EAACI Treasurer
Marek Jutel
Poland
marek.jutel@umed.wroc.pl

EAACI Vice-President Communications & Membership
Karin Hoffmann-Sommergruber
Austria
Karin.Hoffmann-Sommergruber@meduniwien.ac.at

EAACI Vice-President Congresses
Carsten Schmidt-Weber
Germany
csweber@turn.de

EAACI Vice President Education & Specialty
Peter Schmid-Grendelmeier
Switzerland
Peter.Schmid@usz.ch

EAACI Past President
Antonella Muraro
Italy
muraro@centroallergiealimentari.eu

Executive Director HQ
Sue C. C. Paredi
Switzerland
sue.paredi@eaaci.org
<table>
<thead>
<tr>
<th>EAACI Role</th>
<th>Name</th>
<th>Lastname</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair, Asthma Section</td>
<td>Zuzana</td>
<td>Diamant</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Chair, Dermatology Section</td>
<td>Knut</td>
<td>Brockow</td>
<td>Germany</td>
</tr>
<tr>
<td>Chair, ENT Section</td>
<td>Philippe</td>
<td>Gevaert</td>
<td>Belgium</td>
</tr>
<tr>
<td>Chair, Basic &amp; Clinical Immunology Section</td>
<td>Jürgen</td>
<td>Schwarze</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chair, Pediatrics Section</td>
<td>Montserrat</td>
<td>Alvaro Lozano</td>
<td>Spain</td>
</tr>
<tr>
<td>Chair, JM Assembly</td>
<td>Ibon</td>
<td>Eguiluz-Gracia</td>
<td>Spain</td>
</tr>
<tr>
<td>Interest Group Representative</td>
<td>Oliver</td>
<td>Pfaar</td>
<td>Germany</td>
</tr>
<tr>
<td>Interest Group Representative</td>
<td>Maria</td>
<td>Torres</td>
<td>Spain</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Antti</td>
<td>Lauerma</td>
<td>Finland</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Isabel</td>
<td>Skypala</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Stefano</td>
<td>Del Giacco</td>
<td>Italy</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Jose Maria</td>
<td>Olaguibel</td>
<td>Spain</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Liam</td>
<td>O’Mahony</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Susanne</td>
<td>Lau</td>
<td>Germany</td>
</tr>
</tbody>
</table>
Presidential Programme
2017-2019
Any other Business?